VC
Value Add VC
โšกHomePulseโšกHelpful Apps๐Ÿ“Blog
โ† Value Add PulseIPOS-1 filed

SaaS-Security Startup Spin AI Files S-1 for an IPO

Spin AI, which builds AI-driven security and data-protection software for SaaS applications, filed a Form S-1 with the SEC to go public. The filing adds an enterprise-security name to a widening IPO pipeline, riding demand for tools that protect the sprawling stack of cloud apps companies now run.

Spin AI
Filer
Form S-1
Filing
SaaS security + data protection
Focus
Enterprise IT/security
Buyer
TC
Trace Cohen
Early-stage VC & angel ยท Founder, New York Venture Partners
June 23, 2026
1 min read
KEY TAKEAWAYS FOR VCs & FOUNDERS
1

SaaS-security and data protection is a durable enterprise budget line, not a hype cycle

2

An S-1 filing tests public appetite for profitable, infrastructure-flavored software names

3

AI-driven security tooling is in demand as attack surfaces and automation both expand

4

It broadens the IPO pipeline beyond AI labs and chips into applied enterprise software

TC
The VC Read ยท Trace's TakeTrace Cohen

SaaS security is the boring-but-bankable corner of the IPO pipeline, and that's exactly why a Spin AI filing is a useful signal: it tests whether public markets still pay for durable, non-hype software or only chase frontier AI narratives. The thesis is sound -- every app a company adds is new attack surface, and protecting SaaS data is a budget line that survives downturns. The 'AI' in the name is increasingly table stakes, not differentiation, so read the filing for real net retention and margins. If it prices cleanly, it tells you the window is open for substance, not just story.

๐Ÿ“ˆ 2026 IPO Tracker โ†’๐Ÿ“Š IPO Pipeline โ†’

Spin AI filed a Form S-1 with the SEC, advancing the enterprise-security company toward a public listing. Spin AI builds software that secures and protects data across SaaS applications -- automating backup, ransomware protection and risk assessment for the dozens or hundreds of cloud apps a modern enterprise depends on.

The category sits on durable demand. As organizations move ever more critical data into SaaS platforms, securing that footprint becomes a non-discretionary budget line, and AI-driven tooling promises to keep pace with a growing, automated threat landscape. That gives a company like Spin AI a steadier revenue story than many of the speculative names crowding the AI cycle.

โ€œSpin AI filed a Form S-1 with the SEC, advancing the enterprise-security company toward a public listing.โ€

The S-1 widens an IPO pipeline that has skewed toward frontier AI labs and semiconductors, adding an applied enterprise-software name. How public investors receive it will be a useful gauge of appetite for practical, infrastructure-flavored software businesses versus the headline AI stories that have dominated recent attention.

ShareXLinkedInEmail

Originally reported by SEC EDGAR (Form S-1). Analysis and editorial commentary by Value Add Pulse.

โ† Back to Pulse

Markets Now

live
SPCXโ–ฒ+1.03%
$226.40
CBRSโ–ผ-1.02%
$321.10
SPYโ–ฒ+0.11%
5,938.20
QQQโ–ฒ+0.09%
19,990.40
NVDAโ–ฒ+0.58%
$155.10
MSFTโ–ฒ+0.27%
$478.60
GOOGLโ–ฒ+0.24%
$208.40
METAโ–ผ-0.34%
$649.20

Read Next

IPO

OpenAI and Anthropic File Confidential S-1s, Racing to Public Markets

OpenAI and Anthropic have both confidentially filed S-1s, with OpenAI targeting a Q4 2026 listing as Anthropic -- fresh off a ~$65B round lifting its valuation toward $965B -- races it to public markets. When both labs trade, every MANGOS member will be in public hands.

IPOIPO imminent

Low-Power Chipmaker Ambiq Micro Files S-1MEF, Racing Toward an Imminent IPO Pricing

Ambiq Micro, the ultra-low-power semiconductor company whose chips power wearables and edge-AI devices, filed an S-1MEF with the SEC -- a registration that companies submit immediately before an IPO prices. The filing signals Ambiq is in the final stretch toward going public as appetite for chip and edge-AI names returns.

IPOS-1 filed

Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go Public

Liminatus Pharma, a clinical-stage biotech developing cancer immunotherapies, filed a Form S-1 with the SEC for an IPO. The filing is a sign of life in the long-dormant biotech IPO market, which has lagged the tech-led reopening.

@Trace_Cohenยทt@nyvp.com